[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
D Jeremic, L Jiménez-Díaz, JD Navarro-López - Ageing research reviews, 2021 - Elsevier
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
[HTML][HTML] Alzheimer's disease: risk factors and potentially protective measures
MVF Silva, CMG Loures, LCV Alves… - Journal of biomedical …, 2019 - Springer
Alzheimer's disease (AD) is the most common type of dementia and typically manifests
through a progressive loss of episodic memory and cognitive function, subsequently causing …
through a progressive loss of episodic memory and cognitive function, subsequently causing …
Dementia in Down syndrome: unique insights for Alzheimer disease research
IT Lott, E Head - Nature Reviews Neurology, 2019 - nature.com
Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …
[HTML][HTML] Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric Aβ and tau species
XQ Chen, WC Mobley - Frontiers in Neuroscience, 2019 - frontiersin.org
Alzheimer disease (AD) represents an oncoming epidemic that without an effective
treatment promises to exact extraordinary human and financial burdens. Studies of …
treatment promises to exact extraordinary human and financial burdens. Studies of …
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …
disease and are at very high risk of developing early-onset dementia, which is now the …
Association of Alzheimer disease with life expectancy in people with Down syndrome
MF Iulita, DG Chavez, MK Christensen… - JAMA network …, 2022 - jamanetwork.com
Importance People with Down syndrome have a high risk of developing Alzheimer disease
dementia. However, penetrance and age at onset are considered variable, and the …
dementia. However, penetrance and age at onset are considered variable, and the …
Down syndrome
Trisomy 21, the presence of a supernumerary chromosome 21, results in a collection of
clinical features commonly known as Down syndrome (DS). DS is among the most …
clinical features commonly known as Down syndrome (DS). DS is among the most …
Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr682-phosphorylated APP βCTF
Lysosome dysfunction arises early and propels Alzheimer's disease (AD). Herein, we show
that amyloid precursor protein (APP), linked to early-onset AD in Down syndrome (DS), acts …
that amyloid precursor protein (APP), linked to early-onset AD in Down syndrome (DS), acts …
[HTML][HTML] Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses
XQ Chen, WC Mobley - Frontiers in neuroscience, 2019 - frontiersin.org
Alzheimer disease (AD) represents an oncoming epidemic that without an effective
treatment promises to exact extraordinary financial and emotional burdens. Studies of …
treatment promises to exact extraordinary financial and emotional burdens. Studies of …
[HTML][HTML] Targeting amyloidogenic processing of APP in Alzheimer's disease
Alzheimer's disease (AD) is the most common type of senile dementia, characterized by
neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were …
neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were …